Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Kidney Transplant Rejection
Interventions
DRUG

AT-1501

IV infusions of AT-1501 20 mg/kg over 1 hour.

DRUG

Tacrolimus

Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.

Trial Locations (56)

5000

Royal Adelaide Hospital, Adelaide

6150

Fiona Stanley Hospital, Perth

10016

New York University Langone Health - Tisch Hospital, New York

10029

Mount Sinai Medical Center, New York

10032

Columbia University Irving Medical Center / New York Presbyterian Hospital, New York

17104

University of Pittsburgh Medical Center, Harrisburg

20007

Medstar Georgetown University Hospital, Washington D.C.

21201

University of Maryland Medical Center, Baltimore

21287

Johns Hopkins University, Baltimore

23298

Virginia Commonwealth University, Richmond

27710

Duke University Medical Center, Durham

30322

Emory University Hospital, Atlanta

30912

Augusta University, Augusta

33606

Tampa General Hospital, Tampa

40202

University of Louisville, Louisville

45219

University of Cincinnati Medical Center, Cincinnati

46202

Indiana University School of Medicine, Indianapolis

48202

Henry Ford Health System, Detroit

53792

University of Wisconsin Health, Madison

55455

University of Minnesota Medical Center, Minneapolis

55907

Mayo Clinic, Rochester

60153

Loyola University Medical Center, Maywood

60637

University of Chicago, Chicago

63110

Washington University in St. Louis, St Louis

66160

University of Kansas Medical Center, Kansas City

68198

University of Nebraska Medical Center, Omaha

70112

Tulane Medical Center, New Orleans

75235

UT Southwestern, Dallas

80045

University of Colorado Hospital, Aurora

87042

Centre Hospitalier Universitaire Dupuytren, Limoges

90024

University of California Los Angeles, Los Angeles

90033

Keck School of Medicine of USC, Los Angeles

92868

University of California, Irvine Medical Center, Orange

94143

University of California, San Francisco, San Francisco

95817

University of California, Davis Medical Center, Sacramento

97239

Oregon Health and Science University, Portland

98195

University of Washington Medical Center, Seattle

02114

Massachusetts General Hospita;, Boston

02115

Brigham and Women's Hospital, Boston

Unknown

Fundação Oswaldo Ramos - Hospital do Rim, São Paulo

Hospital das Clínicas da Faculdade de Medicina de São Paulo, São Paulo

St. Paul's Hospital, Vancouver

Vancouver General Hospital, Vancouver

Hopital de Bois-Guillaume, Bois-Guillaume

Groupe Hospitalier Pellegrin, Bordeaux

Henri Mondor Hospital, Créteil

CHU Grenoble-Alpes - Hopital Nord Michallon, Grenoble

CHU de Toulouse - Hopital de Rangueil, Toulouse

CHRU Tours - Hopital Bretonneau, Tours

Charite Universitatsmedizin Berlin, Berlin

Hospital Germans Trias i Pujol, Barcelona

Hospital Universitari de Bellvitge, Barcelona

T6G 2B7

University of Alberta Hospital, Edmonton

08003

Hospital del Mar - Parc de Salut Mar, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Eledon Pharmaceuticals

INDUSTRY

NCT05983770 - Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | Biotech Hunter | Biotech Hunter